|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turtoi A, Peixoto P, Castronovo V and
Bellahcene A: Histone deacetylases and cancer-associated
angiogenesis: Current understanding of the biology and clinical
perspectives. Crit Rev Oncog. 20:119–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meattini I, Curigliano G, Terziani F,
Becherini C, Airoldi M, Allegrini G, Amoroso D, Barni S, Bengala C,
Guarneri V, et al: SAFE trial: An ongoing randomized clinical study
to assess the role of cardiotoxicity prevention in breast cancer
patients treated with anthracyclines with or without trastuzumab.
Med Oncol. 34:752017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu L, Wu K, Ma S and Zhang S: HDAC
inhibitors: A new radiosensitizer for non-small-cell lung cancer.
Tumori. 101:257–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marti RM, Sorolla A and Yeramian A: New
therapeutic targets in melanoma. Actas Dermosifiliogr. 103:579–590.
2012.(In English; In Spanish). PubMed/NCBI
|
|
8
|
Eigl BJ, North S, Winquist E, Finch D,
Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, et al: A
phase II study of the HDAC inhibitor SB939 in patients with
castration resistant prostate cancer: NCIC clinical trials group
study IND195. Invest New Drugs. 33:969–976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schech A, Kazi A, Yu S, Shah P and Sabnis
G: Histone deacetylase inhibitor entinostat inhibits
tumor-initiating cells in triple-negative breast cancer cells. Mol
Cancer Ther. 14:1848–1857. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen
YA, Chiou YS, Ho SY, Lin P and Wang YJ: Suberoylanilide hydroxamic
acid, an inhibitor of histone deacetylase, enhances
radiosensitivity and suppresses lung metastasis in breast cancer in
vitro and in vivo. PloS One. 8:e763402013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee
KH, Kim TY, Han SW, Oh DY, Kim TY, et al: Histone deacetylase
inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances
anti-tumor effects of the poly (ADP-ribose) polymerase (PARP)
inhibitor olaparib in triple-negative breast cancer cells. Breast
Cancer Res. 17:332015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou
JL, Feng CR, Fang QH, Wang HH, Zhang PF, et al: The histone
deacetylase inhibitor suberoylanilide hydroxamic acid induces
growth inhibition and enhances taxol-induced cell death in breast
cancer. Cancer Chemother Pharmacol. 66:1131–1140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong C, Qu S, Lv XB, Liu B, Tan W, Nie Y,
Su F, Liu Q, Yao H and Song E: BRMS1L suppresses breast cancer
metastasis by inducing epigenetic silence of FZD10. Nat Commun.
5:54062014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Martile M, Del Bufalo D and
Trisciuoglio D: The multifaceted role of lysine acetylation in
cancer: Prognostic biomarker and therapeutic target. Oncotarget.
7:55789–55810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bennett M, Macdonald K, Chan SW, Luzio JP,
Simari R and Weissberg P: Cell surface trafficking of Fas: A rapid
mechanism of p53-mediated apoptosis. Science. 282:290–293. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zuckerman V, Wolyniec K, Sionov RV, Haupt
S and Haupt Y: Tumour suppression by p53: The importance of
apoptosis and cellular senescence. J Pathol. 219:3–15.
2009.PubMed/NCBI
|
|
19
|
Vousden KH: Apoptosis. p53 and PUMA: A
deadly duo. Science. 309:1685–1686. 2005.
|
|
20
|
Hikisz P and Kilianska ZM: PUMA, a
critical mediator of cell death-one decade on from its discovery.
Cell Mol Biol Lett. 17:646–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alaee M, Khaghani S, Behroozfar K, Hesari
Z, Ghorbanhosseini SS and Nourbakhsh M: Inhibition of nicotinamide
phosphoribosyltransferase induces apoptosis in estrogen
receptor-positive MCF-7 breast cancer cells. J Breast Cancer.
20:20–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zuco V, Cassinelli G, Cossa G, Gatti L,
Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V,
Cincinelli R, et al: Targeting the invasive phenotype of
cisplatin-resistant non-small cell lung cancer cells by a novel
histone deacetylase inhibitor. Biochem Pharmacol. 94:79–90. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang H, Shang YP, Chen HY and Li J:
Histone deacetylases function as novel potential therapeutic
targets for cancer. Hepatol Res. 47:149–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin TY, Fenger J, Murahari S, Bear MD,
Kulp SK, Wang D, Chen CS, Kisseberth WC and London CA: AR-42, a
novel HDAC inhibitor, exhibits biologic activity against malignant
mast cell lines via down-regulation of constitutively activated
Kit. Blood. 115:4217–4225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zimmerman B, Sargeant A, Landes K,
Fernandez SA, Chen CS and Lairmore MD: Efficacy of novel histone
deacetylase inhibitor, AR42, in a mouse model of, human
T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res.
35:1491–1497. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang S, Suvannasankha A, Crean CD, White
VL, Chen CS and Farag SS: The novel histone deacetylase inhibitor,
AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell
cycle arrest in multiple myeloma cells. Int J Cancer. 129:204–213.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Balch C, Naegeli K, Nam S, Ballard B,
Hyslop A, Melki C, Reilly E, Hur MW and Nephew KP: A unique histone
deacetylase inhibitor alters microRNA expression and signal
transduction in chemoresistant ovarian cancer cells. Cancer Biol
Ther. 13:681–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen YJ, Wang WH, Wu WY, Hsu CC, Wei LR,
Wang SF, Hsu YW, Liaw CC and Tsai WC: Novel histone deacetylase
inhibitor AR-42 exhibits antitumor activity in pancreatic cancer
cells by affecting multiple biochemical pathways. PloS One.
12:e01833682017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu YS, Chou CH, Tzen KY, Gao M, Cheng AL,
Kulp SK and Cheng JC: Radiosensitizing effect of a
phenylbutyrate-derived histone deacetylase inhibitor in
hepatocellular carcinoma. Int J Radiat Oncol Biol Phys.
83:e181–e189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li DR, Zhang H, Peek E, Wang S, Du L, Li G
and Chin AI: Synergy of histone-deacetylase inhibitor AR-42 with
cisplatin in bladder cancer. J Urol. 194:547–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lv XB, Wu W, Tang X, Wu Y, Zhu Y, Liu Y,
Cui X, Chu J, Hu P, Li J, et al: Regulation of SOX10 stability via
ubiquitination-mediated degradation by Fbxw7α modulates melanoma
cell migration. Oncotarget. 6:36370–36382. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wagner T, Brand P, Heinzel T and Krämer
OH: Histone deacetylase 2 controls p53 and is a critical factor in
tumorigenesis. Biochim Biophys Acta. 1846:524–538. 2014.PubMed/NCBI
|
|
34
|
Tang Y, Zhao W, Chen Y, Zhao Y and Gu W:
Acetylation is indispensable for p53 activation. Cell. 133:612–626.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Souza C and Chatterji BP: HDAC
inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer
Drug Discov. 10:145–162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Coates AS, Millar EK, O'Toole SA, Molloy
TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z,
Castiglione-Gertsch M, et al: Prognostic interaction between
expression of p53 and estrogen receptor in patients with
node-negative breast cancer: Results from IBCSG Trials VIII and IX.
Breast Cancer Res. 14:R1432012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wilking MJ, Singh C, Nihal M, Zhong W and
Ahmad N: SIRT1 deacetylase is overexpressed in human melanoma and
its small molecule inhibition imparts anti-proliferative response
via p53 activation. Arch Biochem Biophys. 563:94–100. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim JH, Yoon EK, Chung HJ, Park SY, Hong
KM, Lee CH, Lee YS, Choi K, Yang Y, Kim K and Kim IH: p53
acetylation enhances Taxol-induced apoptosis in human cancer cells.
Apoptosis. 18:110–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ito A, Kawaguchi Y, Lai CH, Kovacs JJ,
Higashimoto Y, Appella E and Yao TP: MDM2–HDAC1-mediated
deacetylation of p53 is required for its degradation. EMBO J.
21:6236–6245. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zheng S, Koh XY, Goh HC, Rahmat SAB, Hwang
LA and Lane DP: Inhibiting p53 acetylation reduces cancer
chemotoxicity. Cancer Res. 77:4342–4354. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Taieb J, Tabernero J, Mini E, Subtil F,
Folprecht G, van Laethem JL, Thaler J, Bridgewater J, Petersen LN,
Blons H, et al: Oxaliplatin, fluorouracil, and leucovorin with or
without cetuximab in patients with resected stage III colon cancer
(PETACC-8): An open-label, randomised phase 3 trial. Lancet Oncol.
15:862–873. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han Q, Chen R, Wang F, Chen S, Sun X, Guan
X, Yang Y, Peng B, Pan X Li J, et al: Pre-exposure to 50
Hz-electromagnetic fields enhanced the antiproliferative efficacy
of 5-fluorouracil in breast cancer MCF-7 cells. PloS One.
13:e01928882018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Di Gennaro E, Bruzzese F, Pepe S, Leone A,
Delrio P, Subbarayan PR, Avallone A and Budillon A: Modulation of
thymidilate synthase and p53 expression by HDAC inhibitor
vorinostat resulted in synergistic antitumor effect in combination
with 5FU or raltitrexed. Cancer Biol Ther. 8:782–791. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bode AM and Dong Z: Post-translational
modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805.
2004. View Article : Google Scholar : PubMed/NCBI
|
